What is the recommended dosing regimen for azithromycin (including oral and intravenous routes) in adults and children, and how should the dose be adjusted in hepatic impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Azithromycin Dosing Regimen

For most clinical indications, azithromycin should be dosed as 500 mg on day 1 followed by 250 mg daily on days 2-5 in adults, and 10 mg/kg (max 500 mg) on day 1 followed by 5 mg/kg (max 250 mg) daily on days 2-5 in children over 6 months. 1, 2

Adult Dosing

Oral Administration

Standard 5-day regimen (most common indications):

  • Day 1: 500 mg as a single dose
  • Days 2-5: 250 mg once daily
  • Total course: 1.5 grams over 5 days 1, 2

This regimen applies to:

  • Community-acquired pneumonia (mild severity)
  • Pharyngitis/tonsillitis (second-line)
  • Uncomplicated skin/skin structure infections
  • Pertussis treatment and prophylaxis 1, 2

Alternative 3-day regimen:

  • 500 mg once daily for 3 days
  • Used for acute bacterial exacerbations of COPD and acute bacterial sinusitis 2

Single-dose regimens:

  • Chlamydial infections (non-gonococcal urethritis/cervicitis): 1 gram single dose 3, 4, 2
  • Gonococcal urethritis/cervicitis: 2 grams single dose 2
  • Chancroid: 1 gram single dose 2

Intravenous Administration

For severe community-acquired pneumonia:

  • 500 mg IV once daily (infused over 1 hour at 2 mg/mL concentration, or over 3 hours at 1 mg/mL concentration)
  • Continue until clinical improvement, then switch to oral therapy
  • Total treatment duration: 7-10 days (IV + oral combined) 5

For severe babesiosis (hospitalized patients):

  • 500 mg IV once daily until symptoms abate, then convert to oral 250-500 mg daily
  • Total treatment typically 7-10 days 6
  • For immunocompromised patients, a one-time loading dose of 1000 mg IV has been used, followed by 500 mg daily 6

Pediatric Dosing

Infants Under 6 Months

For pertussis (treatment and prophylaxis):

  • Infants <6 months: 10 mg/kg once daily for 5 days 1
  • This is the preferred macrolide for infants <1 month due to lower risk of infantile hypertrophic pyloric stenosis compared to erythromycin 1

Critical safety note: Infants <1 month receiving any macrolide should be monitored for infantile hypertrophic pyloric stenosis and other serious adverse events 1

Children 6 Months and Older

Standard 5-day regimen:

  • Day 1: 10 mg/kg (maximum 500 mg)
  • Days 2-5: 5 mg/kg once daily (maximum 250 mg per day)
  • Total course: 30 mg/kg over 5 days 1, 2

Alternative 3-day regimen (acute otitis media, acute bacterial sinusitis):

  • 10 mg/kg once daily for 3 days 2

Single-dose regimen (acute otitis media only):

  • 30 mg/kg as a single dose 2

For severe babesiosis (hospitalized children):

  • 10 mg/kg (max 500 mg) IV once daily until symptoms abate, then convert to oral 5-10 mg/kg (max 500 mg) daily
  • Total treatment typically 7-10 days 6

Children with Chlamydial Infections

  • Weight <45 kg: Erythromycin 50 mg/kg/day divided into 4 doses for 14 days (azithromycin not recommended in this weight range for chlamydia) 3, 4
  • Weight >45 kg but age <8 years: 1 gram single dose 3, 4
  • Age ≥8 years: 1 gram single dose 3, 4

Hepatic Impairment

Azithromycin should be prescribed with caution in patients with impaired hepatic function. 1 However, no specific dose adjustment is required based on available pharmacokinetic data 2, 7.

The evidence shows that in patients with mild to moderate hepatic impairment (Child-Pugh class A and B cirrhosis), azithromycin pharmacokinetics do not differ consistently from healthy volunteers 7. Mean residence time was slightly higher in class B patients, but AUC, volume of distribution, total clearance, and renal clearance were similar across groups 7.

Practical approach:

  • Monitor liver function tests during therapy
  • Watch for signs of hepatotoxicity (jaundice, dark urine, abdominal pain)
  • Consider alternative antibiotics if severe hepatic impairment (Child-Pugh class C) is present, as data are lacking in this population 2

Renal Impairment

No dosage adjustment is recommended for patients with renal impairment (GFR ≤80 mL/min). 2 The mean AUC was similar in subjects with GFR 10-80 mL/min compared to normal renal function, but increased 35% in subjects with GFR <10 mL/min 2.

Exercise caution when administering azithromycin to patients with severe renal impairment (GFR <10 mL/min). 2 While no specific dose reduction is mandated, closer monitoring is prudent.

Important Clinical Considerations

Drug Interactions and Administration

  • Do not take azithromycin simultaneously with aluminum- or magnesium-containing antacids as they reduce absorption 1
  • Monitor patients taking drugs metabolized by cytochrome P450 (digoxin, triazolam, ergot alkaloids) 1
  • Can be taken with or without food (oral formulations) 2

Common Pitfalls

  1. Underdosing in children with streptococcal pharyngitis: Research demonstrates that 60 mg/kg total course (not the standard 30 mg/kg) is more effective for Group A streptococcal eradication 8. However, this higher dose is not reflected in current FDA labeling 2.

  2. Inappropriate use for community-acquired pneumonia: Many patients receive azithromycin without meeting criteria for severe CAP or atypical pathogen coverage, and without baseline ECG assessment for QTc prolongation risk 9.

  3. Re-dosing after vomiting: If a pediatric patient vomits within 30 minutes of receiving the 30 mg/kg single dose for otitis media, re-dosing at the same total dose has been done in clinical trials, though safety data are limited 2.

Pregnancy and Lactation

Azithromycin is FDA Pregnancy Category B 1. It is considered safe for use in pregnant women, including for chlamydial infections where it is the preferred agent (1 gram single dose) 4.

Monitoring Requirements

  • Infants <1 month: Monitor for infantile hypertrophic pyloric stenosis 1
  • All patients: Watch for QTc prolongation, especially with IV administration or in patients with risk factors
  • Hepatic impairment: Monitor liver function tests during therapy 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.